New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Halozyme Therapeutics, Inc.
HALO
Shape
US Flag

NASDAQ

6B

Biotechnology

Next Earning date - 31 Oct 2024

6B

Biotechnology

Next Earning date - 31 Oct 2024

49.25USD
Shape-0.05 ( -0.10%)
favorite-chart

Relative Strenght

83
favorite-chart

Volume Buzz

-44%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

25%

Quote Panel

Shape
Updated October 27, 2024
1W -4.87 % 1M -13.96 % 3M -11.21 % 1Y 44.85 %

Key Metrics

Shape
  • Market Cap

    6.24B


  • Shares Outstanding

    126.68M


  • Share in Float

    125.30M


  • Dividende

    0


  • Earning Date

    31 Oct 2024


  • Price Target

    49.25


  • Average Volume

    1.34M


  • Beta

    1.271


  • Range

    33.07-65.53


  • Industry

    Biotechnology


  • Website

    https://www.halozyme.com


  • Sector

    Healthcare


Fundamentals

Shape

15.06x

P/E Ratio

7.14x

P/S Ratio

21.63x

P/B Ratio

5.3

Debt/Equity

38.6%

Net Margin

$2.6

EPS

How HALO compares to sector?

P/E Ratio

Relative Strength

Shape

HALO

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$1B

Shape394%

2025-Revenue

$4.15

Shape469%

2025-EPS

$410M

Shape198%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wells Fargo

downgrade

Previous: Market Outperform

2024-10-07

Now: Equal-Weight

Piper Sandler

downgrade

Previous: Overweight

2024-06-06

Now: Neutral

Piper Sandler

upgrade

Previous: Not converted

2023-05-10

Now: Overweight

Wells Fargo

initialise

Previous: Not converted

2022-11-28

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+35%

0.74
vs 0.55

Q4.22

arrow
arrow

+14%

0.48
vs 0.42

Q1.23

arrow
arrow

N/A

0.47
vs 0.47

Q2.23

arrow
arrow

+40%

0.74
vs 0.53

Q3.23

arrow
arrow

+1%

0.75
vs 0.74

Q4.23

arrow
arrow

+71%

0.82
vs 0.48

Q1.24

arrow
arrow

+68%

0.79
vs 0.47

Q2.24

arrow
arrow

+23%

0.91
vs 0.74

Q3.24

arrow
arrow

+31%

0.98
vs 0.75

Q4.24

arrow
arrow

+58%

1.3
vs 0.82

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+80%

209M  vs 115.8M

Q4.22

arrow
arrow

+78%

181.5M  vs 102M

Q1.23

arrow
arrow

+38%

162.1M  vs 117.3M

Q2.23

arrow
arrow

+45%

221M  vs 152.4M

Q3.23

arrow
arrow

+3%

216M  vs 209M

Q4.23

arrow
arrow

+27%

230M  vs 181.5M

Q1.24

arrow
arrow

+21%

195.9M  vs 162.1M

Q2.24

arrow
arrow

+5%

231.4M  vs 221M

Q3.24

arrow
arrow

+16%

251.1M  vs 216M

Q4.24

arrow
arrow

+34%

307.9M  vs 230M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+64%

0.64
vs 0.08

Q4.22

arrow
arrow

+34%

0.34
vs 0.64

Q1.23

arrow
arrow

+60%

0.6
vs 0.34

Q2.23

arrow
arrow

+49%

0.49
vs 0.6

Q3.23

arrow
arrow

+33%

0.33
vs 0.49

Q4.23

arrow
arrow

+102%

1.02
vs 0.33

Q1.24

arrow
arrow

+43%

0.43
vs 1.02

Q2.24

arrow
arrow

+32%

0.32
vs 0.43

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

359

359
vs 371

-3%

Q4.22

arrow
arrow

438

438
vs 359

22%

Q1.23

arrow
arrow

392

392
vs 438

-10%

Q2.23

arrow
arrow

382

382
vs 392

-3%

Q3.23

arrow
arrow

400

400
vs 382

5%

Q4.23

arrow
arrow

421

421
vs 400

5%

Q1.24

arrow
arrow

420

420
vs 421

0%

Q2.24

arrow
arrow

458

458
vs 420

9%

Earnings Growth

Latest News